Mike Briley

The young Englishman, Peter Bennett, came to visit this beautiful and peaceful valley deep in Southern France to forget the infidelity of his ex-fiancé with his ex-best friend. Getting lost and accidentally discovering a strange well with possible connections to the Cathars and their treasure, being enrolled by an ex-pat Brit into a dubious property swindle and a whirlwind romance with a gorgeous older woman certainly take his mind off his amorous deception in the UK. These events and his naïve enthusiasm, however, entangle him in a deadly international intrigue where no one is quite who they originally appeared to be. An ordinary person in an extraordinary situation, can Peter find within himself the resources he needs to survive and to find a way out of this tangle? This is a revised version of the story originally published in 2008 under the title 'The Well'.

The Valley of Discord

M. Marien

Noradrenergic Mechanisms in Parkinson's Disease examines fundamental and clinical evidence explaining the progression of the disease. Featuring contributions from acknowledged international experts in the field, this book defines ideopathic Parkinson's disease and covers such topics as the alterations in Parkinson's disease, norepinephrine-dopamine interactions, noradrenergic control of striatal dopamine release, glial cells as targets of the central noradrenergic systems, and a theory regarding noradrenergic mechanisms in Parkinson's disease. New directions for research on Parkinson's disease are also explored.

Noradrenergic Mechanisms in Parkinson's Disease

David Nutt

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

Mike Briley

Books

Your next favorite book is out there